Loading...
01/11 11:06
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call shows strong financial performance with a 63% increase in total revenue and a significant increase in software and drug discovery revenues. Despite a net loss, the company has a strong cash position and reduced operating expenses. The Q&A section reveals confidence in their R&D and software offerings, with no immediate threats from competitors. The lack of a shareholder return plan is a minor downside. Overall, the positive revenue growth and strategic collaborations are likely to result in a positive stock price movement.
Total Revenue $59.6 million, an increase of 63% compared to Q1 2024, driven by higher software and drug discovery revenue.
Software Revenue $48.8 million, an increase of 46% compared to Q1 2024, driven by larger customer renewals and expansions of pre-existing contracts.
Drug Discovery Revenue $10.7 million, compared to $3.2 million in Q1 2024, driven by recognition of upfront payment from Novartis and expanded collaborations.
Software Cost of Revenue $13.5 million in Q1, compared to $8 million in Q1 2024, due to expenses associated with the Gates Predictive Tox Initiative.
Software Gross Margin 72%, compared to 76% in Q1 2024, due to changes in revenue mix associated with the Gates grant.
Drug Discovery Cost of Revenue $14.9 million, increased from $9.7 million, driven by higher costs from Novartis collaboration and increased research staff allocation.
Overall Gross Margin 52%, similar to overall gross margin in Q1 2024.
R&D Expense $46 million, down from $50.6 million in Q1 2024, due to staff allocation shifts and lower preclinical CRO expenses.
Sales and Marketing Expense $10.4 million, an increase of 2% due to slightly higher FTE expenses.
G&A Expense $25.8 million, an increase of 1% driven by slight increases in professional services.
Total Operating Expenses $82 million, down from $86 million in Q1 2024, mainly due to lower R&D expenses.
Net Loss After Taxes $60 million or $0.82 per share, compared to a net loss of $54.7 million or $0.76 per share in Q1 2024.
Net Operating Cash Flow $144 million, compared to cash use of $39 million in Q1 2024, driven by the receipt of the upfront payment from Novartis.
Cash and Marketable Securities Balance Increased from $367 million on December 31 to $512 million at the end of Q1.
Current Liabilities Decreased by 14%.
Total Deferred Revenue Declined by 5% to $210 million.
Change in Fair Value of Equity Method Investments Loss of $13 million, compared to a gain of $8 million in Q1 2024.
Other Income $4.2 million, down from $5 million in Q1 2024, due to lower cash balance and yields.
Total Other Expense Loss of $8.9 million, compared to a gain of $13 million in Q1 2024.
Software Updates: Released second software update of the year with enhancements including new crystal structure prediction software and expanded support for protein degrader modeling.
Predictive Toxicology Initiative: Continuing to advance predictive toxicology initiative with a beta release expected later this year.
Drug Discovery Revenue: Drug discovery revenue increased to $10.7 million, driven by collaborations, including Novartis.
Software Revenue Growth: Software revenue grew by 46% to $48.8 million, with strong contributions from larger customer renewals and expansions.
Operating Expenses: Operating expenses declined year-over-year to $82 million from $86 million in Q1 2024.
Cash Position: Cash marketable securities balance increased from $367 million to $512 million.
Clinical Trials: Initial Phase I data expected from three lead clinical programs, starting with SGR-1505.
Financial Guidance: Full year 2025 financial guidance remains unchanged, expecting software revenue growth of 10% to 15%.
Macroeconomic Environment: Management acknowledged potential challenges posed by the macroeconomic environment, although they remain optimistic about revenue growth.
Regulatory Issues: There is uncertainty regarding potential new tariffs or trade barriers that could impact the pharmaceutical industry and its profitability.
Customer Purchase Reluctance: Currently, there is no resistance or reluctance to purchase from customers, but management is monitoring for any new policies or regulations that could affect R&D investments.
Currency Fluctuations: Currency has negatively impacted reported revenue growth from international markets, but changing exchange rates may provide modest benefits later in the year.
Biologics vs. Small Molecules: Uneven treatment of biologics and small molecules has been a headwind for software sales, but recent executive orders may alleviate this issue.
Revenue Exposure to China: Direct revenue exposure to China is minimal, with low single-digit percentages of software revenue coming from Chinese entities.
Software Revenue Growth: Software revenue was $48.8 million, representing 46% growth compared to Q1 2024.
Drug Discovery Revenue: Drug Discovery revenue for the quarter was $10.7 million, driven by milestones from collaborative programs and recognition of upfront revenue from Novartis.
Predictive Toxicology Initiative: Continuing to advance predictive toxicology initiative with a beta release expected later this year.
Clinical Trials: Initial Phase I data from three lead clinical programs expected to be shared starting this quarter.
Software Update: Released second software update of the year with major enhancements including new crystal structure prediction software.
Full Year 2025 Revenue Guidance: Expect software revenue growth of 10% to 15% and drug discovery revenue in the range of $45 million to $50 million.
Operating Expense Growth: Expect operating expense growth to be less than 5% for the year.
Q2 2025 Software Revenue Guidance: Expect software revenue in Q2 to be in the range of $38 million to $42 million.
Cash Burn: Expect cash burn this year to be significantly below last year's cash burn.
Software Gross Margin Guidance: Expect full year software gross margin to be in the range of 74% to 75%.
Shareholder Return Plan: None
The earnings call revealed mixed sentiments. While there is optimism about long-term profitability and strategic partnerships, challenges such as delayed software growth and uncertain monetization timelines for new projects persist. The company's focus on discovery partnerships and reduced expenses are positive, but the lack of concrete guidance on key initiatives tempers enthusiasm. Given the market cap, the stock price is likely to remain stable in the short term, with a neutral prediction.
The earnings call reveals mixed signals. Strong software revenue growth and a promising predictive toxicology initiative are positive. However, the cautious guidance and shift in clinical data timeline could dampen enthusiasm. The Q&A highlights demand consistency and constructive renewal discussions but lacks clarity on key metrics. The market cap suggests moderate reactions, leading to a neutral sentiment.
The earnings call shows strong financial performance with a 63% increase in total revenue and a significant increase in software and drug discovery revenues. Despite a net loss, the company has a strong cash position and reduced operating expenses. The Q&A section reveals confidence in their R&D and software offerings, with no immediate threats from competitors. The lack of a shareholder return plan is a minor downside. Overall, the positive revenue growth and strategic collaborations are likely to result in a positive stock price movement.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
